Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp

Recursion Pharmaceuticals (NASDAQ:RXRX) had its price objective reduced by equities research analysts at KeyCorp from $12.00 to $10.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s target price would suggest a potential upside of 37.74% from the stock’s current price.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Price Performance

RXRX opened at $7.26 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a 1 year low of $5.60 and a 1 year high of $15.74. The stock’s 50 day simple moving average is $6.93 and its 200 day simple moving average is $7.03. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of -4.75 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. During the same period last year, the business earned ($0.43) EPS. As a group, analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the sale, the director now directly owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,341 shares of company stock valued at $393,490 in the last three months. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in RXRX. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after buying an additional 4,626,268 shares during the last quarter. State Street Corp grew its stake in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. Lingotto Investment Management LLP increased its position in shares of Recursion Pharmaceuticals by 69.0% during the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. Ghisallo Capital Management LLC bought a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $8,250,000. Finally, Perceptive Advisors LLC bought a new stake in Recursion Pharmaceuticals during the second quarter valued at approximately $5,769,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.